01/02/2022 - 16:09

Chimeric signs research agreement with US university

01/02/2022 - 16:09


Upgrade your subscription to use this feature.

Clinical-stage cell therapy company, Chimeric Therapeutics has signed a three-year sponsored research agreement with the University of Pennsylvania in the US to support its ongoing development of gastric and colorectal cancer fighting therapies. According to Chimeric, the research will focus on further developing its cutting-edge treatments through pre-clinical studies, correlative research and cell therapy on candidates.

Subscribe today for award-winning, unbiased and trusted journalism

Subscription Options